Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

NCT01027377 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Hemophilia A

Interventions

DRUG: rFVIIIFc
DRUG: rFVIIIFc

Sponsor

Bioverativ Therapeutics Inc.